<DOC>
	<DOCNO>NCT00003633</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose combination chemotherapy treat patient advanced prostate cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerated dos docetaxel mitoxantrone combination fix dose estramustine prednisone , give patient advanced prostate cancer . - Characterize toxicity treatment regimen patient . OUTLINE : This dose escalation study mitoxantrone docetaxel . Patients stratify one two risk group ( good risk group poor risk group ) base number prior chemotherapy regimen ( ) occurrence site ( ) prior radiation . All patient receive oral prednisone twice daily day 0-3 , oral estramustine three time daily day 1-5 , mitoxantrone IV bolus day 2 , docetaxel IV 1 hour day 2 . Courses repeat every 21 day absence unacceptable toxicity disease progression . Patients stable disease may go treatment 6 course . Dose escalation proceeds independently risk group . Cohorts 3 patient enter risk group . If 1 3 patient dose level experience dose limit toxicity ( DLT ) , 3 additional patient accrue level . If 2 6 patient dose level experience DLT , dose escalation stop maximum tolerate dose ( MTD ) define previous dose level . At least 6 patient must treat MTD . Patients follow every 3 month death . PROJECTED ACCRUAL : At least 12 patient ( 6 risk group ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Failure complete androgen ablation ( orchiectomy LHRH antiandrogen therapy ) manifest least 1 follow criterion : Rise serum PSA great 50 % nadir confirm 2 measurement 1 week apart Appearance new lesion bone scan Appearance new softtissue lesion Measurable evaluable disease No brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN SGOT SGPT great 2 time ULN Renal : Creatinine great 2 time ULN Cardiovascular : No history coagulopathy No myocardial infarction last 6 month No history cardiovascular accident No history congestive heart failure Neurological : No symptomatic peripheral neuropathy great grade 1 No history significant neurologic psychiatric disorder include psychotic disorder , dementia , seizures Pulmonary : No history pulmonary embolus Other : Testosterone great 3.5 nmol/L No contraindication glucocorticoid therapy uncontrolled diabetes mellitus active peptic ulcer disease No active infection No serious illness medical condition No concurrent prior malignancy past 5 year except previously excise curatively irradiated nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior hormonal therapy ( include nonsteroidal antiandrogens , LHRH agonists ) Radiotherapy : No prior radiotherapy great 30 % bone marrow At least 6 week since isotope therapy At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>